Glimepiride Zentiva

Glimepiride Zentiva is a prescription oral tablet that contains the active ingredient glimepiride, a second‑generation sulfonylurea. It is marketed in the European Union and is used as an antidiabetic medication. The product works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus.

Glimepiride Zentiva is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient. It is typically prescribed as part of a comprehensive treatment plan that may include other oral agents or insulin.

- Improves glycemic control in adults with type 2 diabetes. - Used as monotherapy or in combination with other antidiabetic drugs. - Helps reduce fasting and post‑prandial blood glucose levels. - May be considered when sulfonylurea therapy is appropriate. - Supports long‑term management of diabetes alongside lifestyle modifications.

Glimepiride Zentiva may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common: - Low blood sugar (hypoglycemia). - Nausea or upset stomach. - Headache. - Dizziness. - Weight gain. - Skin rash or itching.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as swelling of the face, lips, or throat. - Liver function abnormalities. - Blood disorders like leukopenia or thrombocytopenia. - Pancreatitis symptoms (abdominal pain, vomiting).

Before starting Glimepiride Zentiva, certain health considerations should be reviewed to minimize risks and ensure safe use.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Monitor blood glucose regularly to detect hypoglycemia early. - Use cautiously in elderly patients who may be more susceptible to low blood sugar. - Evaluate for a history of allergic reactions to sulfonylureas. - Discuss pregnancy or breastfeeding plans with a healthcare provider. - Adjust dose if the patient is taking other medications that affect glucose levels. - Advise patients to carry identification indicating they are on a sulfonylurea.

Glimepiride Zentiva can interact with several other medicines, altering its effectiveness or increasing the risk of side effects.

Avoid: - Other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride levels. - MAO‑B inhibitors, which may enhance hypoglycemic effects.

Use with caution: - Beta‑blockers, as they may mask hypoglycemia symptoms. - Thiazide diuretics, which can increase blood glucose. - Corticosteroids, which may reduce the drug’s glucose‑lowering effect. - Antifungal agents like itraconazole, requiring closer glucose monitoring. - NSAIDs, which can affect renal function and glucose control.